SCHEMBL20249277

SCHEMBL20249277

CC(C)(C)c1ccc(OC2CCCNC2)nn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.44
CHRNA4 P43681 3/20 0.44
ROCK1 Q13464 7/20 0.40
ROCK2 O75116 2/20 0.40
KCNH2 Q12809 1/20 0.40
CNR2 P34972 1/20 0.38
HTR1A P08908 1/20 0.37
SLC6A2 P23975 1/20 0.37
MKNK1 Q9BUB5 2/20 0.37
PIM1 P11309 2/20 0.36
PIM2 Q9P1W9 2/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
PRKX P51817 1/20 0.36
PRKCE Q02156 1/20 0.36
PRKCD Q05655 1/20 0.36
PRKD1 Q15139 1/20 0.36
IKBKB O14920 2/20 0.35
CHUK O15111 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20249279 0.92 CHRNB2 (0.41) CHRNB2CHRNA4ROCK1ROCK2HTR1A
SCHEMBL20249274 0.85 SLC6A2 (0.37) HTR1ASLC6A2CHRM1
SCHEMBL18291291 0.81 CHRNB2 (0.47) CHRNB2CHRNA4ROCK1ROCK2KCNH2
SCHEMBL11908645 0.78 CHRNB2 (0.50) CHRNB2CHRNA4ROCK1ROCK2KCNH2
SCHEMBL20038023 0.78 CHRNB2 (0.47) CHRNB2CHRNA4ROCK1ROCK2KCNH2
SCHEMBL20249299 0.77 CHRNB2 (0.56) CHRNB2CHRNA4ROCK1ROCK2KCNH2
SCHEMBL20249298 0.76 CLK2 (0.40) PIM1PIM2
SCHEMBL20249297 0.76 CLK2 (0.40) PIM1PIM2
SCHEMBL20249286 0.76 CLK2 (0.32) PIM1PIM2
SCHEMBL28680550 0.74 CHRNB2 (0.46) CHRNB2CHRNA4ROCK1ROCK2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 CHRNB2 4863/4885CHRNA4 4628/4885ROCK1 2915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.